Mendus secures manufacturing partner for

TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical firm targeted on immunotherapies addressing tumor recurrence, at present introduced an settlement to allow the know-how switch for manufacturing of the corporate’s lead improvement program DCP-001 with Minaris Regenerative Medicine GmbH (“Minaris”), a number one contract improvement and manufacturing service supplier for the cell and gene remedy trade. DCP-001 is presently being evaluated within the ADVANCE II Phase 2 medical trial to stop circumstances of tumor recurrence in Acute Myeloid Leukemia (AML) and within the ALISON Phase 1 medical trial in ovarian most cancers.

“Based on our in-house process development experience and capabilities we have developed a DCP-001 process optimized for large-scale industrial manufacturing. With DCP-001 in Phase 2 development and considering the encouraging data reported so far, it is time to take the necessary steps now and prepare for a transition into late-stage manufacturing infrastructure,” commented Leopold Bertea, PhD, Chief Technology Officer of Mendus. “We have chosen Minaris as our CDMO and manufacturing partner in consideration of their demonstrated outstanding abilities and track-record, and their focus on the production of cell and gene therapy products.”

Mendus plans to announce up to date outcomes and survival outcomes from the ADVANCE II medical trial evaluating its lead most cancers program DCP-001 as a novel AML upkeep remedy in This autumn 2022. Positive interim outcomes reported in May 2022 have demonstrated a profitable final result on the first examine endpoint of measurable residual illness (MRD), together with first clear alerts that MRD responses translate into related survival profit. Mendus may also current first medical outcomes from the ALISON trial evaluating DCP-001 in ovarian most cancers on the European Society of Gynecological Oncology (ESGO) convention, held October 27-30.

FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting

Chief Executive Officer

E-mail: [email protected]

INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: [email protected]

MEDIA RELATIONS
Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: [email protected]

ABOUT MENDUS AB (PUBL)

Mendus is devoted to altering the course of most cancers remedy by addressing tumor recurrence and bettering survival outcomes for most cancers sufferers, whereas preserving high quality of life. We are leveraging our unparalleled experience in allogeneic dendritic cell biology to develop a sophisticated medical pipeline of novel, off-the-shelf, cell-based immunotherapies which mix medical efficacy with a benign security profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm beneath the ticker IMMU.ST. http://www.mendus.com/

• 221018_Mendus_Minaris_ENG